# An Open Label Clinical Trial of Retinal Gene Therapy for Choroideremia

> **NCT02077361** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Alberta** · enrollment: 6 (actual)

## Conditions studied

- Choroideremia

## Interventions

- **GENETIC:** rAAV2.REP1 vector

## Key facts

- **NCT ID:** NCT02077361
- **Lead sponsor:** University of Alberta
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2017-08-30
- **Final completion:** 2022-05-16
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2022-05-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02077361

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02077361, "An Open Label Clinical Trial of Retinal Gene Therapy for Choroideremia". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02077361. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*